Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lipolysis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Lipolysis. Displaying page 1 of 1.
    EudraCT Number: 2015-004637-27 Sponsor Protocol Number: AZ-01_SGLT-2 Start Date*: 2016-01-21
    Sponsor Name:Medizinische Universität Graz
    Full Title: A randomized, double-blind, three arm, three treatment period, cross-over trial to investi-gate the effect of a SGLT-2 inhibitor, a DPP-4 inhibitor and a SGLT-2 inhibitor + DPP-4 inhibitor on gluca...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10012594 Diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005013-11 Sponsor Protocol Number: D2452L00007 Start Date*: 2005-02-01
    Sponsor Name:Umeå University Hospital
    Full Title: A 36 wk three-center double-blind randomized three-way cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo. The MEDICA study Mechanisms for the diabetes-p...
    Medical condition: The "metabolic syndrome" is a cluster of metabolic and cardiovascular risk factors. Insulin resistance appears to be a central disease mechanism and hypertension is another important component. A t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002094-38 Sponsor Protocol Number: 0584 Start Date*: 2016-12-29
    Sponsor Name:University of Leicester
    Full Title: The Effect of an SGLT2 inhibitor on Glucose Flux, Lipolysis and Ketogenesis following insulin withdrawal in people with absolute or relative endogenous insulin deficiency
    Medical condition: Type 1 and Type 3c diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-004878-17 Sponsor Protocol Number: 0.1 Start Date*: 2017-07-20
    Sponsor Name:University of Leicester
    Full Title: The Effect of a SGLT2 inhibitor on Glucose flux, Lipolysis and Exercise in type 2 Diabetes
    Medical condition: Type 2 diabetes.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-002606-40 Sponsor Protocol Number: CLCZ696B2207 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A randomized, double-blind, parallel group study to evaluate metabolic effects of LCZ696 and amlodipine in obese hypertensive subjects
    Medical condition: Mild to moderate essential hypertension in obese subjects
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-005075-40 Sponsor Protocol Number: 2013-005075-40 Start Date*: 2014-04-08
    Sponsor Name:Research Programs' Unit, Diabetes & Obesity, University of Helsinki
    Full Title: The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003426-28 Sponsor Protocol Number: CBXIGT Start Date*: 2007-08-10
    Sponsor Name:University Hospitals Birmingham NHS Trust
    Full Title: Cortisol metabolism and impaired glucose tolerance
    Medical condition: Impared glucose tolerance
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018429 Glucose tolerance impaired LLT
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004373-10 Sponsor Protocol Number: p08- Start Date*: 2008-04-08
    Sponsor Name:Top institute of Pharmaceutical Research
    Full Title: The effect of short term Topiramate treatment on insulin secretion, glucose- and lipid metabolism in obese women
    Medical condition: Obesity Diabetes Mellitus Metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003432-39 Sponsor Protocol Number: D1690L00016 Start Date*: 2014-11-19
    Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
    Full Title: A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with e...
    Medical condition: Obesity defined as body mass index (BMI) 30-45 kg/m2 Obesity related metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004149-26 Sponsor Protocol Number: METRIS-HF(EMPA) Start Date*: 2018-06-26
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction
    Medical condition: Heart Failure with reduced ejection fraction (HFrEF and HFmrEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003146-75 Sponsor Protocol Number: BETA3_LVH Start Date*: 2016-03-14
    Sponsor Name:Université catholique de Louvain (UCL)
    Full Title: A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with struct...
    Medical condition: Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10019290 Heart insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) GR (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002568-27 Sponsor Protocol Number: PM-C-0172 Start Date*: 2006-05-08
    Sponsor Name:Sanofi-Synthelabo Groupe
    Full Title: A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with...
    Medical condition: Abdominally obese patients with metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DK (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018708-99 Sponsor Protocol Number: 1245.39 Start Date*: 2010-10-19
    Sponsor Name:BOEHRINGER ING.
    Full Title: An open-label, phase IIb study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor ...
    Medical condition: patients with IGT or type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 LLT
    9.1 10018429 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:58:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA